A 28-year-old woman with newly diagnosed sputum-smear-positive pulmonary TB is started on standard first-line anti-TB therapy. After 2 months of treatment, repeat sputum examination shows persistent acid-fast bacilli (AFB) on microscopy. What is the most appropriate next investigation to assess treatment response and detect possible drug resistance?